3 steps for taking on Novartis in radiopharma: Curium up first

{
  "signal_id": "5381254c-94dd-02d3-e678-9f05b9c36d4c",
  "signal_type": "news",
  "signal_subtype": "has_revenue",
  "detected_at": "2026-09-29T06:09:55+00:00",
  "company": {
    "name": "Novartis",
    "domain": "novartis.com"
  },
  "data": {
    "url": "https://www.biospace.com/business/3-steps-for-taking-on-novartis-in-radiopharma-curium-up-first",
    "title": "3 steps for taking on Novartis in radiopharma: Curium up first - biospace.com",
    "excerpt": "Novartis’ blockbuster radioligand therapy business faces emerging threats. Curium received FDA approval for Bexlutry, its rival to Novartis’ Lutathera, in September, and the biotech is in talks with the agency about a filing for a separate radiopharma treatment that could challenge the Swiss drugmaker’s Pluvicto. Meanwhile, after agreeing to a $1.65 billion buyout of ITM Isotope Technologies Munich, Telix Pharmaceuticals will soon own therapies that could compete with both Novartis products. The stakes are high. Lutathera and Pluvicto generated $1.7 billion over the first half of the year. Sales of the products are increasing at a time when Novartis’ growth prospects face scrutiny. Competition could increase pressure on Novartis, but the unique, exacting requirements of radioligand therapy (RLT) supply mean FDA approval is only one step toward a viable challenge for treatments currently on the market. To compete, Curium and other potential challengers will need to master three steps. Access to lutetium-177 (Lu-177), the radioactive isotope in Lutathera, Pluvicto and Curium’s challengers, is the foundation of RLT supply. While the University of Missouri Research Reactor provides Lu-177 to Novartis, Curium has established multiple lines to produce its own Lu-177, North America CEO Michael Patterson told BioSpace in August, making it currently the only vertically integrated RLT...",
    "summary": "Novartis generated $1.7 billion in revenue from its radioligand therapies Lutathera and Pluvicto in the first half of the year.",
    "planning": false,
    "image_url": "https://static.biospace.com/dims4/default/85a62e4/2147483647/strip/true/crop/724x407+0+38/resize/1440x810!/quality/90/?url=https%3A%2F%2Fk1-prod-biospace.s3.us-east-2.amazonaws.com%2Fbrightspot%2Fcf%2Fb4%2Fbbf029cc45f4970b0f236a4d51bc%2Fistock-1264143632.jpg",
    "confidence": 0.9,
    "published_at": "2026-09-29T06:09:55Z",
    "article_sentence": "Lutathera and Pluvicto generated $1.7 billion over the first half of the year.",
    "amount_normalized": 1700000000
  }
}

curl https://signals.autobound.ai/v1/signals/5381254c-94dd-02d3-e678-9f05b9c36d4c \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"novartis.com","limit":20}'